Purchase Order 75F40124P00295
Award Date
7/15/24
Potential Completion Date
9/15/29
Potential Value
$439K
Federal Agency
Food and Drug Administration
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
PSC Category
6640 - Laboratory Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded Illumina, Inc. a firm fixed-price purchase order contract worth $233,747.00 to provide an Illumina NextSeq 2000 Sequencing System and one year of post-warranty maintenance. The contract has an ultimate completion date of October 14, 2026. This award is not associated with a larger contract vehicle and does not have a set-aside designation. Illumina, Inc. is a for-profit manufacturer of sequencing and genomic analysis instruments and reagents....
The Department of Health and Human Services Food and Drug Administration awarded a $534,031 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System to be delivered to Silver Spring, Maryland. The solicitation notice indicated the FDA requires this sequencing system to adapt standard operating procedures for its currently installed Illumina NextSeq 500 model, scale up sequencing...
The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
This is a firm fixed price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for an ILLUMINA NEXTSEQ2000 SEQUENCING SYSTEM. The contract has a ceiling value of $576,928.00 and a completion date of July 20, 2026. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, and has previously received prime federal contract and subcontract awards from agencies such as the National Institutes of Health (NIH), Centers for...
The Department of Health and Human Services Food and Drug Administration awarded a $457,531.00 firm fixed price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract is for the delivery of an ILLUMINA NEXTSEQ 2000 SEQUENCING SYSTEM, plus a preventative maintenance agreement, to be performed in Silver Spring, Maryland. This award does not have a set-aside designation. Illumina has a history of providing sequencing systems and related...
The Department of Health and Human Services Food and Drug Administration awarded a $169,505.48 firm fixed price purchase order to Illumina, Inc. of Laurel, Maryland for an Illumina NextSeq 50 System Check. The contract has a period of performance through February 10, 2025 to deliver product care services for the NextSeq 50 sequencing system. No set-aside provisions were applied to this award made by the FDA to support its regulatory and public health responsibilities through genomic analysis...
The FDA awarded a $186,405.00 firm-fixed-price purchase order contract to Illumina, Inc. for a service agreement covering a NextSeq 500 sequencing system. This contract has no set-aside designation. The purpose is to ensure reliable operation of the FDA's next-generation sequencing instrument used to analyze DNA, RNA, and DNA-protein interactions to inform regulatory decision-making. The contract provides for parts, labor, reagent replacement, preventative maintenance, technical support,...
The U.S. Food and Drug Administration awarded a $219,300 firm fixed price purchase order to Illumina, Inc. for a NextSeq 2000 Sequencing System. This award was not subject to any set-aside provisions. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has been awarded past federal contracts with agencies such as the NIH, CDC, USDA, and VA to provide a range of sequencing systems and related products. The award references an original small business...
This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the delivery of a "HIGH-THROUGHPUT DESKTOP SEQUENCER WITH DATA ANALYSIS SYSTEM" and has a ceiling value of $426,000.30. There is no set-aside designation for this contract. Illumina has previously provided a range of sequencing systems, reagents, and...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $341,700 purchase order to Illumina, Inc. to provide one (1) Illumina NextSeq 2000 System. The place of performance for this firm fixed price contract is Silver Spring, Maryland. The period of performance is from September 29, 2022 through October 29, 2023. The NextSeq 2000 System is a benchtop high-throughput sequencing platform that enables DNA and RNA sequencing applications. No applicable...